StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Regenxbio's ebitda for the twelve months ending Jun 30, 2026 was -$148.78M. For fiscal 2025 it was -$145.58M. The highest annual figure on record is $169.54M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$145.58M–
FY2024Dec 31, 2024-$217.13M–
FY2023Dec 31, 2023-$250.81M–
FY2022Dec 31, 2022-$249.97M-247.4%
FY2021Dec 31, 2021$169.54M–
FY2020Dec 31, 2020-$110.83M–
FY2019Dec 31, 2019-$141.85M-254.0%
FY2018Dec 31, 2018$92.08M–
FY2017Dec 31, 2017-$73.20M–
FY2016Dec 31, 2016-$64.80M–
FY2015Dec 31, 2015-$23.06M–
FY2014Dec 31, 2014-$3.68M–
FY2013Dec 31, 2013-$4.78M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$33.02M–
Q1 FY2026Mar 31, 2026-$79.51M-594.4%
Q4 FY2025Dec 31, 2025-$53.77M–
Q3 FY2025Sep 30, 2025-$48.53M–
Q2 FY2025Jun 30, 2025-$59.37M–
Q1 FY2025Mar 31, 2025$16.08M–
Q4 FY2024Dec 31, 2024-$47.35M–
Q3 FY2024Sep 30, 2024-$58.12M–
Q2 FY2024Jun 30, 2024-$51.99M–
Q1 FY2024Mar 31, 2024-$59.68M–
Q4 FY2023Dec 31, 2023-$59.57M–
Q3 FY2023Sep 30, 2023-$60.59M–
Q2 FY2023Jun 30, 2023-$68.67M–
Q1 FY2023Mar 31, 2023-$61.98M–
Q4 FY2022Dec 31, 2022-$53.65M-117.0%
Q3 FY2022Sep 30, 2022-$67.50M–
Q2 FY2022Jun 30, 2022-$59.89M–
Q1 FY2022Mar 31, 2022-$68.94M–
Q4 FY2021Dec 31, 2021$316.20M–
Q3 FY2021Sep 30, 2021-$54.52M-438.1%
Q2 FY2021Jun 30, 2021-$50.03M–
Q1 FY2021Mar 31, 2021-$42.11M–
Q4 FY2020Dec 31, 2020-$51.55M–
Q3 FY2020Sep 30, 2020$16.13M–
Q2 FY2020Jun 30, 2020-$39.70M–
Q1 FY2020Mar 31, 2020-$35.71M–
Q4 FY2019Dec 31, 2019-$38.40M-1121.0%
Q3 FY2019Sep 30, 2019-$34.03M–
Q2 FY2019Jun 30, 2019-$35.12M-584.7%
Q1 FY2019Mar 31, 2019-$34.29M-133.3%
Q4 FY2018Dec 31, 2018$3.76M–
Q3 FY2018Sep 30, 2018-$21.78M–
Q2 FY2018Jun 30, 2018$7.25M–
Q1 FY2018Mar 31, 2018$102.86M–
Q4 FY2017Dec 31, 2017-$15.88M–
Q3 FY2017Sep 30, 2017-$20.60M–
Q2 FY2017Jun 30, 2017-$14.35M–
Q1 FY2017Mar 31, 2017-$22.37M–
Q4 FY2016Dec 31, 2016-$20.19M–
Q3 FY2016Sep 30, 2016-$18.51M–

More Regenxbio figures

See a number that looks wrong?